ReviewCurrent opinion in chemical biology2017
Recent progress in developing selective inhibitors of protein methyltransferases.
Review in Current opinion in chemical biology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 41 citations in OpenAlex.
- Trained immunity: novel perspectives in diabetes and associated complications.Frontiers in immunology · 2025Review
- Recent advances in developing degraders & inhibitors of lysine methyltransferases.Current opinion in chemical biology · 2023Review
- Development of Potent and Selective Coactivator-Associated Arginine Methyltransferase 1 (CARM1) Degraders.Journal of medicinal chemistry · 2023Article
- Inhibition of histone methyltransferase PRMT5 attenuates cisplatin-induced hearing loss through the PI3K/Akt-mediated mitochondrial apoptotic pathway.Journal of pharmaceutical analysis · 2023Article
- Arginine methylation in the epithelial-to-mesenchymal transition.The FEBS journal · 2022Review
- Article
- The Histone Demethylase HR Suppresses Breast Cancer Development through Enhanced CELF2 Tumor Suppressor Activity.Cancers · 2022Article
- Purification and Identification of Natural Inhibitors of Protein Arginine Methyltransferases from Plants.Molecular and cellular biology · 2022Article
- How Protein Methylation Regulates Steroid Receptor Function.Endocrine reviews · 2022Review
- Migration and Adhesion of B-Lymphocytes to Specific Microenvironments in Mantle Cell Lymphoma: Interplay between Signaling Pathways and the Epigenetic Landscape.International journal of molecular sciences · 2021Review
- A Chemical Probe for the Methyl Transferase PRMT5 with a Novel Binding Mode.ACS medicinal chemistry letters · 2020Article
- Histone lysine methyltransferases in biology and disease.Nature structural & molecular biology · 2019Review
- Targeting protein methylation: from chemical tools to precision medicines.Cellular and molecular life sciences : CMLS · 2019Review
- Discovery of Potent and Selective Covalent Protein Arginine Methyltransferase 5 (PRMT5) Inhibitors.ACS medicinal chemistry letters · 2019Article
- PRMT1 loss sensitizes cells to PRMT5 inhibition.Nucleic acids research · 2019Article
- Protein arginine methyltransferase 5: A novel therapeutic target for triple-negative breast cancers.Cancer medicine · 2019Article
- Role of PRMT5 in bladder cancer: a comprehensive study.Translational cancer research · 2019Article
- Lysine methylation of transcription factors in cancer.Cell death & disease · 2019Review
- Chemical and Biochemical Perspectives of Protein Lysine Methylation.Chemical reviews · 2018Review
- Investigations on small molecule inhibitors targeting the histone H3K4 tri-methyllysine binding PHD-finger of JmjC histone demethylases.Bioorganic & medicinal chemistry · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Mounting evidence suggests that protein methyltransferases (PMTs), which catalyze methylation of histones as well as non-histone proteins, play a crucial role in diverse biological pathways and human diseases. In particular, PMTs have been recognized as major players in regulating gene expression and chromatin state. There has been an increasingly growing interest in these enzymes as potential therapeutic targets and over the past two years tremendous progress has been made in the discovery of selective, small molecule inhibitors of protein lysine and arginine methyltransferases. Inhibitors of PMTs have been used extensively in oncology studies as tool compounds, and inhibitors of EZH2, DOT1L and PRMT5 are currently in clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.